AU2022324471A1 — 1'-alkyl modified ribose derivatives and methods of use
Assigned to Sanegene Bio USA Inc · Expires 2024-02-15 · 2y expired
What this patent protects
The present disclosure provides linker compounds of Formula (I) or (II) pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. More specifically, linker compounds of formulas (l-A), (Il-A) are provided: The present disclosure also relates to uses of the …
USPTO Abstract
The present disclosure provides linker compounds of Formula (I) or (II) pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. More specifically, linker compounds of formulas (l-A), (Il-A) are provided: The present disclosure also relates to uses of the linker compounds, scaffolds, and conjugates, e.g., in delivering nucleic acid and/or treating or preventing diseases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.